CA2343471A1 - Characterization of an antibiotic impregnated delivery system as an intracanal medicament in endodontic therapy - Google Patents
Characterization of an antibiotic impregnated delivery system as an intracanal medicament in endodontic therapy Download PDFInfo
- Publication number
- CA2343471A1 CA2343471A1 CA002343471A CA2343471A CA2343471A1 CA 2343471 A1 CA2343471 A1 CA 2343471A1 CA 002343471 A CA002343471 A CA 002343471A CA 2343471 A CA2343471 A CA 2343471A CA 2343471 A1 CA2343471 A1 CA 2343471A1
- Authority
- CA
- Canada
- Prior art keywords
- fiber
- intracanal
- endodontic
- treatment site
- incorporated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Endodontic fibers comprising a biocompatible polymer vehicle permeable to medicaments, or combinations of medicaments are described. Such fibers can be used, for example, in a method for the local delivery and sustained release of medicaments to periodontal or intracanal treatment sites. Endodontic fibers described include modified periodontal fibers and intracanal fibers.
Claims (20)
1. An endodontic fiber suitable for the local delivery and sustained release of one or more medicaments incorporated therein to an intracanal treatment site, comprising a copolymer vehicle having incorporated therein one or more medicaments.
2. The endodontic fiber of Claim 1, wherein the medicament is selected form the group consisting of antibiotics, anti-inflammatory agents, antimicrobial agents, immune reagents, and immunomodulatory agents or a combination thereof.
3. The endodontic fiber of Claim 2, wherein the medicament is an antibiotic selected from the group consisting of clindamycin, tetracyline and combinations thereof.
4. The endodontic fiber of Claim 1, wherein the fiber is an ethylene vinyl acetate copolymer having a diameter of from about 0.1 mm to about 2.0 mm and the antibiotic is clindamycin incorporated at a dose of about 2.0 mg to about 5.0 mg mg per 10 mm of fiber.
5. The endodontic fiber of Claim 2, wherein the medicament comprises a combination of an antibiotic and an anti-inflammatory agent.
6. A modified periodontal fiber suitable for the delivery and sustained release of medicament incorporated therein to an intracanal treatment site, comprising a copolymer vehicle having incorporated therein one or more medicaments, wherein the copolymer is treated to decrease its surface tackiness and increase its rigidity.
7. A method for the local delivery and sustained release of a medicament to an intracanal treatment site comprising the steps of:
(a) obtaining an endodontic fiber suitable for intracanal use having one or more medicaments incorporated therein;
(b) positioning the fiber of (a) in the root canal such that the fiber is in direct contact with the treatment site; and (c) maintaining the fiber at the treatment site, whereby the medicament is delivered to the treatment site at a controlled rate.
(a) obtaining an endodontic fiber suitable for intracanal use having one or more medicaments incorporated therein;
(b) positioning the fiber of (a) in the root canal such that the fiber is in direct contact with the treatment site; and (c) maintaining the fiber at the treatment site, whereby the medicament is delivered to the treatment site at a controlled rate.
8. The method of Claim 7, wherein the endodontic fiber is selected from the group consisting of a modified periodontal fiber or an intracanal fiber.
9. A method of treating an endodontic bacterial infection comprising the steps of:
(a) obtaining an endodontic fiber suitable for intracanal use having one or more medicaments incorporated therein;
(b) inserting the fiber of (a) into the root canal such that the fiber is in direct contact with the treatment site; and (c) maintaining the fiber at the treatment site, whereby the antibiotic is delivered to the treatment site.
(a) obtaining an endodontic fiber suitable for intracanal use having one or more medicaments incorporated therein;
(b) inserting the fiber of (a) into the root canal such that the fiber is in direct contact with the treatment site; and (c) maintaining the fiber at the treatment site, whereby the antibiotic is delivered to the treatment site.
10. The method of Claim 9, wherein the endodontic fiber is selected from the group consisting of a modified periodontal fiber or an intracanal fiber.
11. A method of disinfecting a root canal receiving endodontic treatment comprising the steps of:
(a) obtaining an endodontic fiber suitable for intracanal use having one or more medicaments incorporated therein;
(b) inserting the fiber of (a) into a debrided and irrigated root canal such that the fiber is in direct contact with the treatment site; and (c) maintaining the fiber at the treatment site, whereby the medicament is administered to the treatment site at a controlled rate.
(a) obtaining an endodontic fiber suitable for intracanal use having one or more medicaments incorporated therein;
(b) inserting the fiber of (a) into a debrided and irrigated root canal such that the fiber is in direct contact with the treatment site; and (c) maintaining the fiber at the treatment site, whereby the medicament is administered to the treatment site at a controlled rate.
12. The method of Claim 11, wherein the endodontic fiber is selected from the group consisting of a modified periodontal fiber or an intracanal fiber.
13. A method of reducing inflamation in periapical tissue of a tooth undergoing endodontic treatment, comprising the steps of:
(a) obtaining an endodontic fiber suitable for intracanal use having incorporated therein an anti-inflammatory agent;
(b) positioning the fiber into a debrided and irrigated root canal such that the fiber is in direct contact with the inflamed tissue; and (c) maintaining the endodontic fiber at the treatment site, whereby the anti-inflammatory agent is delivered to the site of inflammation.
(a) obtaining an endodontic fiber suitable for intracanal use having incorporated therein an anti-inflammatory agent;
(b) positioning the fiber into a debrided and irrigated root canal such that the fiber is in direct contact with the inflamed tissue; and (c) maintaining the endodontic fiber at the treatment site, whereby the anti-inflammatory agent is delivered to the site of inflammation.
14. The method of Claim 13, wherein the endodontic fiber is selected from the group consisting of a modified periodontal fiber or an intracanal fiber.
15. An intracanal fiber which is an ethylene vinyl acetate copolymer comprising less than about 20% vinyl acetate.
16. An intracanal fiber according to Claim 15, comprising less than about 15%
vinyl acetate.
vinyl acetate.
17. An intracanal fiber according to Claim 15, comprising less than about 10%
vinyl acetate.
vinyl acetate.
18. An intracanal fiber according to Claim 15, comprising about 9.3% vinyl acetate.
19. An intracanal fiber according to Claim 15, having a diameter of less than about 0.5 mm.
20. An intracanal fiber according to Claim 18, having a diameter of less than about 0.5 mm and one or more medicament incorporated therein.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/963,880 US6712610B2 (en) | 1999-04-02 | 2001-09-26 | Characterization of an antibiotic impregnated delivery system as an intracanal medicament in endodontic therapy and method |
US10/812,638 US7331787B2 (en) | 1999-04-02 | 2004-03-29 | Characterization of an antibiotic impregnated delivery system as an intracanal medicament in endodontic therapy |
US11/957,936 US7946849B2 (en) | 1999-04-02 | 2007-12-17 | Characterization of an antibiotic impregnated delivery system as an intracanal medicament in endodontic therapy |
US13/113,670 US20120028222A1 (en) | 1999-04-02 | 2011-05-23 | Characterization of an antibiotic imregnated delivery systems as an intracanal medicament in endodontic therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24000400P | 2000-10-12 | 2000-10-12 | |
US60/240,004 | 2000-10-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2343471A1 true CA2343471A1 (en) | 2002-04-12 |
CA2343471C CA2343471C (en) | 2009-12-15 |
Family
ID=22904687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002343471A Expired - Fee Related CA2343471C (en) | 1999-04-02 | 2001-03-30 | Characterization of an antibiotic impregnated delivery system as an intracanal medicament in endodontic therapy |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2343471C (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120021384A1 (en) * | 2008-12-12 | 2012-01-26 | Stashenko Philip P | Characterization of an antibiotic imregnated delivery systems as an intracanal medicament in endodontic therapy |
-
2001
- 2001-03-30 CA CA002343471A patent/CA2343471C/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120021384A1 (en) * | 2008-12-12 | 2012-01-26 | Stashenko Philip P | Characterization of an antibiotic imregnated delivery systems as an intracanal medicament in endodontic therapy |
Also Published As
Publication number | Publication date |
---|---|
CA2343471C (en) | 2009-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1252730A (en) | Intra-pocket drug delivery devices for treatment of periodontal diseases | |
CA2029046C (en) | Sustained release compositions for treating periodontal disease | |
US7946849B2 (en) | Characterization of an antibiotic impregnated delivery system as an intracanal medicament in endodontic therapy | |
EP1392364B1 (en) | Liquid polymer composition for prevention and treatment of the oral cavity diseases | |
WO1999008691A3 (en) | Use of locally delivered metal ions for treatment of periodontal disease | |
US20110044917A1 (en) | Dental composition for treating peri-implantitis | |
CA2506997A1 (en) | Controlled drug delivery using polymer macromolecules to retard drug elution | |
JP2004501063A5 (en) | ||
Killoy | Chemical treatment of periodontitis: local delivery of antimicrobials | |
CA2243274A1 (en) | Male contraceptive implant | |
CA2465133A1 (en) | Low concentration of peroxide for treating or preventing vaginal infections | |
CA2370784A1 (en) | Endodontic fibers and methods of use therefor | |
CA2343471A1 (en) | Characterization of an antibiotic impregnated delivery system as an intracanal medicament in endodontic therapy | |
JP2002541085A5 (en) | ||
MY122454A (en) | Use of oxazolidinones for the preparation of a medicament for transdermal delivery | |
JPH01311031A (en) | Carrier for dental external drug | |
Lakshmi Priya et al. | Local Drug Delivery–An Overview | |
JP2005041838A (en) | Biofilm-eliminating agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20190401 |